Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 912

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 5
Chunk 912
---
stock split of our then outstanding shares of common stock. Accordingly, each 8 shares of outstanding common stock then held by our
stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to
the next whole share. Authorized common stock remained at 60,000,000 shares
following the stock split. The accompanying consolidated financial statements and accompanying notes have been retroactively revised
to reflect such reverse stock split as if it had occurred on April 1, 2023. All shares and per share amounts have been revised
accordingly.

WARRANT
INDUCEMENT 

In March 2025, the Company
entered into a warrant inducement agreement resulting in the issuance of 1,550,000 new warrants and the modification of 775,000 existing
warrants. The fair value of the new warrants and the incremental fair value from the modification totaled $4,612,862 which was recorded
as a non-cash inducement expense in other expense and reflected as an increase to additional paid-in capital.

ISSUANCES OF COMMON STOCK AND WARRANTS

Equity Transactions in the Fiscal Year Ended March 31, 2025.

March 2025 Warrant-Based
Financing

On March 16, 2025, the
Company entered into an inducement offer to exercise existing Class A and Class B Warrants
(the “Agreement”) with a certain accredited and institutional holder (the “Holder”) of the Company’s outstanding
Class A and Class B Warrants issued on May 17, 2024 (the “Existing Warrants”). Pursuant
to the Agreement, the Holder, upon exercise, will receive a new unregistered Common Stock Purchase Warrant (“New Warrant”)
pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (“Securities Act”), to purchase up to a number of shares
equal to 200% of the number of Warrant Shares issued pursuant to the exercise of Existing Warrants pursuant to this Agreement (the “New
Warrant Shares”), which New Warrant shall have an exercise price per share equal to $0.3736, subject to adjustment as provided
in the New Warrant, will be exercisable at any time on or after six (6) months from the date of issuance and have a term of exercise
of five and one-half (5.5) years from the date of issuance and (ii